Profile: Infinity Pharmaceuticals Inc (INFI.O)

INFI.O on Nasdaq

9.11USD
31 Jul 2014
Price Change (% chg)

$-0.31 (-3.27%)
Prev Close
$9.42
Open
$9.27
Day's High
$9.52
Day's Low
$8.98
Volume
429,839
Avg. Vol
474,444
52-wk High
$23.68
52-wk Low
$8.40

Search Stocks

Infinity Pharmaceuticals, Inc. (IPI), incorporated on March 22, 1995, is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90).

PI3K Inhibitor Program

The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company’s lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL). As of December 31, 2012, the Company was in Phase 1, open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics and clinical activity of IPI-145 in patients with advanced hematologic malignancies.

Hsp90 Inhibitor Program

Hsp90 is used for the treatment of a broad range of cancers. Hsp90 is a member of the chaperone system of proteins which serves to maintain the structure and activity of specific proteins within the cell. Retaspimycin HCl, also known as IPI-504, is a small molecule inhibits Hsp90 potently and selectively, thereby inhibiting cancer cell growth.

The Company competes with Genentech, Pfizer, Inc., Novartis AG, Bristol Myers Squibb Company, Exelixis, Inc., Millennium, Synta Pharmaceuticals Corp., Astex Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo, Inc., Debiopharm Group, Exelixis, Inc, Kyowa Hakko Kirin Co. Ltd., Myrexis, Inc., Gilead Sciences, Inc., Amgen, Inc., and TG Therapeutics.

Company Address

Infinity Pharmaceuticals Inc

780 Memorial Drive
CAMBRIDGE   MA   02139
P: +1617.4531000
F: +1617.4531001

Search Stocks